Invivyd Inc

Invivyd Inc

IVVD

Get informed when a big investor buys or sells

+ Follow
Market Cap$231.41M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Invivyd IncInvivyd Inc-2--59%--
$4.30

Current Fair Value

448.1% upside

Undervalued by 448.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$231.41 Million
Enterprise Value$79.72 Million
Dividend Yield$- (-)
Earnings per Share$-0.3
Beta0.71
Outstanding Shares320,435,078

Return

Return on Equity-59.27%ROE
Return on Assets-49.04%
Return on Invested Capital-60.10%

Valuation & Multiples

P/E Ratio-1.99P/E Ratio
PEG-0.98PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue1.37
Enterprise Value to EBIT-0.71
Enterprise Value to Net Income-1
Total Debt to Enterprise0.11
Debt to Equity0.05Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 19, 2026
EPS Estimate
$-0.08
Average shareholder expectation
Revenue Estimate
$20.06 M
Average shareholder expectation

Next Earnings Call

Expected Date
November 5, 2026
EPS Estimate
$-0.11
Average shareholder expectation
Revenue Estimate
$15.04 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.6885 32.22%
Total Calls570,400 1.68%
Total Puts392,700 91.09%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %72.70% 0.43%
Total Invested$203.53M 30.83%
Investors Holding133 13.00%

ESG Score

No data

About Invivyd Inc

2,021 employees

Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antib...